Oxford Cannabinoid Technologies Holdings Plc
Oxford Cannabinoid Technologies Holdings Plc (OCTP.L) Company Profile & Overview
Explore Oxford Cannabinoid Technologies Holdings Plc’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.
Oxford Cannabinoid Technologies Holdings Plc (OCTP.L) Company Profile & Overview
Oxford Cannabinoid Technologies Holdings Plc, a pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based prescription medicines. Its lead drug candidate is OCT461201, a selective CB2 receptor agonist in solid oral dosage form that is in pre-clinical development for use in the treatment of IBS-associated visceral pain, as well as neuropathic pain conditions, including post herpetic neuralgia. The company is also developing OCT130401, which is in pre-clinical development for the treatment of trigeminal neuralgia. Oxford Cannabinoid Technologies Holdings Plc was incorporated in 2017 and is headquartered in London, the United Kingdom.